Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class ITerminatedAug 29, 2018Levothyroxine and LiothyronineFailed Content Uniformity Specifications: Product was manufactured using an adulterated active pharmaceutical ingredient; additionally, lack of process controls and good...Westminster Pharmaceuticals LLC · D-1179-2018Class ITerminatedAug 29, 2018Levothyroxine and LiothyronineFailed Content Uniformity Specifications: Product was manufactured using an adulterated active pharmaceutical ingredient; additionally, lack of process controls and good...Westminster Pharmaceuticals LLC · D-1178-2018Class IICompletedAug 29, 2018Camber PharmaceuticalsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Hetero Labs Limited Unit V · D-1116-2018Class IICompletedAug 29, 2018Camber PharmaceuticalsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Hetero Labs Limited Unit V · D-1115-2018Class IICompletedAug 29, 2018Camber PharmaceuticalsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Hetero Labs Limited Unit V · D-1114-2018Class IICompletedAug 29, 2018Camber PharmaceuticalsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Hetero Labs Limited Unit V · D-1113-2018Class IIITerminatedAug 29, 2018Diltiazem HCl Extended-release CapsulesFailed Impurities/Degradation Specifications; out of specification results for related compound per the manufacturerMylan Institutional, Inc. (d.b.a. UDL Laboratories) · D-1112-2018Class IIOngoingAug 29, 2018Valsartan and Hydrochlorothiazide TabletsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.A-S Medication Solutions LLC. · D-1111-2018Class IIOngoingAug 29, 2018Valsartan and Hydrochlorothiazide TabletsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.A-S Medication Solutions LLC. · D-1110-2018Class IIOngoingAug 29, 2018Valsartan TabletsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.A-S Medication Solutions LLC. · D-1109-2018Class IIOngoingAug 29, 2018Valsartan TabletsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.A-S Medication Solutions LLC. · D-1108-2018Class IITerminatedAug 29, 2018Valsartan Tablets USP 320 mgCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Preferred Pharmaceuticals, Inc · D-1107-2018Class IIITerminatedAug 29, 2018Valsartan Tablets USPIncorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.Jubilant Cadista Pharmaceuticals, Inc. · D-1106-2018Class IIITerminatedAug 29, 2018Valsartan Tablets USPIncorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.Jubilant Cadista Pharmaceuticals, Inc. · D-1105-2018Class IIITerminatedAug 29, 2018Valsartan Tablets USPIncorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.Jubilant Cadista Pharmaceuticals, Inc. · D-1104-2018Class IIITerminatedAug 29, 2018Valsartan Tablets USPIncorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.Jubilant Cadista Pharmaceuticals, Inc. · D-1103-2018Class IITerminatedAug 22, 2018Valsartan 320 mg TabletsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.RemedyRepack Inc. · D-1102-2018Class IITerminatedAug 22, 2018Valsartan 160 mg TabletsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.RemedyRepack Inc. · D-1101-2018Class IITerminatedAug 22, 2018Valsartan 80 mg TabletCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.RemedyRepack Inc. · D-1100-2018Class IIITerminatedAug 22, 2018ContraveDefective Container: Customer complaints of punctures in the bottle.Orexigen Therapeutics, Inc. · D-1099-2018Class IITerminatedAug 22, 2018ValsartanCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Northwind Pharmaceuticals LLC · D-1098-2018Class IITerminatedAug 22, 2018ValsartanCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Northwind Pharmaceuticals LLC · D-1097-2018Class IITerminatedAug 22, 2018Valsartan HCTZCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Northwind Pharmaceuticals LLC · D-1096-2018Class IITerminatedAug 22, 2018ValsartanCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Northwind Pharmaceuticals LLC · D-1095-2018Class IITerminatedAug 22, 2018Papav 300/Phent 5mg/10mLLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1094-2018Class IITerminatedAug 22, 2018P/P/P 0.02/40/2mg/mLLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1093-2018Class IITerminatedAug 22, 2018PRO/PA/PH/AT 18mcg/1.8mg/Lack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1092-2018Class IITerminatedAug 22, 2018PRASH 12.2mcg/1.22m/19.29Lack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1091-2018Class IITerminatedAug 22, 2018P/P/P (Prostaglandin/Papaverine/Phentolamine) InjectionLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1090-2018Class IITerminatedAug 22, 2018Acetylcysteine 10% Oph SolutionLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1089-2018Class IITerminatedAug 22, 2018Medroxprogesterone 1% Ophthalmic SolutionLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1088-2018Class IITerminatedAug 22, 2018Vitamin D3 InjectionLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1087-2018Class IITerminatedAug 22, 2018Dehydrated Alcohol SolutionLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1086-2018Class IITerminatedAug 22, 2018Morphine Sulf inhalationLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1085-2018Class IITerminatedAug 22, 2018PR/PA/PHLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1084-2018Class IITerminatedAug 22, 2018Triple PLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1083-2018Class IITerminatedAug 22, 2018Avastin 1.25 mg/0.05 mL prefilled syringeLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1082-2018Class IITerminatedAug 22, 2018DMSO 6.25% Opth SolLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1081-2018Class IITerminatedAug 22, 2018Atropine 0.01% Opth SolutionLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1080-2018Class IIITerminatedAug 22, 2018Atorvastatin Calcium tabletsFailed Impurities/Degradation Specifications - OOS was observed for ATV Cyclo FP Impurity and Total Degradation Impurities tested at the 18 month stability time point in...Dr. Reddy's Laboratories, Inc. · D-1079-2018